Product Development Stories
Here is why KeyCorp (USA Stocks:KEY) can still attract investors
![]() | over a week ago at Macroaxis By Raphi Shpitalnik |
When it comes to financial fortitude, KeyCorp (NYSE: KEY) stands out as a force to be reckoned with in the Banks - Regional industry. With an enterprise value of $40.3 billion and a solid base of 16.8K full-time employees, KeyCorp's significance in the domestic banking sector is undeniable. The bank's 2024 fiscal year-end figures reveal a compelling narrative. Continue Reading...
- KEY KeyCorp
- Latest Truist Q2 Earnings Top on Higher Fee Income, Costs Dip
- KEY 16.46 0.33
- Low 16.13
- High 16.47
- Volume 14.6 M
- Alpha 0.0775
- Beta 1.64
- Return On Equity 0.06
- Return On Asset 0.0045
- Profit Margin 0.15 %
- Operating Margin 0.23 %
- Current Valuation 37.67 B
- Shares Outstanding 943.2 M
- Shares Owned By Insiders 0.35 %
- Shares Owned By Institutions 81.06 %
- Number Of Shares Shorted 26.52 M
- Price To Earning 10.76 X
- Price To Book 1.12 X
- Price To Sales 2.30 X
- Revenue 10.4 B
- Gross Profit 6.74 B
- EBITDA 3 M
- Net Income 964 M
- Cash And Equivalents 1.78 B
- Cash Per Share 1.91 X
- Total Debt 22.64 B
- Debt To Equity 7.85 %
- Book Value Per Share 13.03 X
- Cash Flow From Operations 2.9 B
- Short Ratio 2.00 X
- Earnings Per Share 0.76 X
- Price To Earnings To Growth 0.74 X
- Target Price 16.94
- Number Of Employees 16.7 K
- Beta 1.25
- Market Capitalization 15.53 B
- Total Asset 188.28 B
- Retained Earnings 15.67 B
- Annual Yield 0.05 %
- Five Year Return 3.74 %
- Net Asset 188.28 B
- Last Dividend Paid 0.82
- Accumulation Distribution 301274.0
- Daily Balance Of Power 0.9706
- Rate Of Daily Change 1.02
- Day Median Price 16.3
- Day Typical Price 16.35
- Price Action Indicator 0.33
- Period Momentum Indicator 0.33
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Rocky Mountain Chocolate, a consumer staples company in the food products sector, has been facing some financial challenges recently. As of the fiscal year end in February, the company reported a loss in operating income of $4.9M, and a substantial income tax expense of $703.8M. Despite the gloomy figures, the enterprise value revenue stands at 0.8069, and the revenue per share is $4.441.
over a week ago at Macroaxis By Aina Ster | ![]() |
Immunoprecise Antibodies (IPA) has recently experienced a minor 3% dip in its stock price, which could present a potential buying opportunity for investors. Despite a negative Jensen Alpha of -0.52 and a net income loss of $26.6 million, the company has shown promising signs of growth with a quarterly revenue growth of 20.3%. Furthermore, with a revenue per share of $0.939, IPA's potential upside of 5.05 indicates that the company's stock could potentially increase in value in the future.
over a week ago at Macroaxis By Vlad Skutelnik | ![]() |
Cintas has a performance score of 11 out of 100. The company's Beta, a measure of market volatility, is 0.66, suggesting potential diversification benefits within a portfolio. As market returns increase, Cintas' returns are expected to rise less than the market.
over two weeks ago at Macroaxis By Ellen Johnson | ![]() |
Our trade recommendation tool can enhance the advice provided by experts on Greenbrier Companies. It evaluates the company's growth potential against your individual risk preferences and investment timeline.
Key Points
Greenbrier Companies (GBX) continues to demonstrate strong financial performance with a return on assets of 3.99% and a net income applicable to common shares of $62.5M. Despite the industry's inherent risks, as indicated by a standard deviation of 1.91, the company's robust earnings, reflected in a PE ratio of 14.32, underscore its potential for value creation and make it a compelling investment opportunity.over two weeks ago at Macroaxis By Aina Ster | ![]() |
Buy low, sell high - a golden rule in investing. Yet, assessing the true value of a stock is where the challenge lies. In the case of Kellanova, a Consumer Defensive company specializing in Food Products, the waters are murky.
over three weeks ago at Macroaxis By Rifka Kats | ![]() |
In the world of finance, it's often said that past performance is not indicative of future results. However, a comprehensive analysis of OP Bancorp's stock performance can provide valuable insights for potential investors. As a domestic bank listed on the NASDAQ, OP Bancorp operates within the financial services industry, specifically in the regional banks sector.
over three weeks ago at Macroaxis By Nico Santiago | ![]() |
In the world of finance, it's often said that past performance is not indicative of future results. This adage rings particularly true when considering the potential for a decline in the value of Morgan Stanley's stock in July. As a titan in the financial services sector, specifically in capital markets, Morgan Stanley (MS.US) boasts a robust market capitalization of $155.2B and a healthy net income from continuing operations of $9.2B.
over a month ago at Macroaxis By Raphi Shpitalnik | ![]() |
Despite the unfavorable news, Qualigen Therapeutics (QLGN) presents potential investment opportunities, particularly for those interested in the biotechnology sector. The company's recent financials show a significant EBITDA loss of 11.3M and an EPS estimate for the current year at -2.7, indicating a challenging financial situation. However, with a day typical price of $0.3 and a slight price change of $0.02, there may be room for growth as the company continues to navigate the healthcare industry.
Main Points
Qualigen Therapeutics holds a Beta of 1.77, indicating a relatively high risk compared to the market.over a month ago at Macroaxis By Vlad Skutelnik | ![]() |
Assure Holdings Corp (IONM) is a player in the Medical Care Facilities industry, with a current quote of $0.43 per share. Despite a recent price change of -$0.05, Wall Street has a target price of $4 for the stock, indicating a potential upside. However, investors should note the company's operating margin of 1.91% and a net interest income reported as a loss of $2.7 million.
over two months ago at Macroaxis By Vlad Skutelnik | ![]() |